76 results on '"Giacomelli, Andrea"'
Search Results
2. Management of enzyme de-induction in a woman with HIV on methadone maintenance switched from nevirapine- to bictegravir-based antiretroviral regimen.
- Author
-
Cattaneo D, Giacomelli A, Casalini G, Ridolfo AL, and Gervasoni C
- Subjects
- Humans, Female, Piperazines therapeutic use, Piperazines administration & dosage, Adult, Pyridones therapeutic use, Pyridones administration & dosage, Opiate Substitution Treatment methods, Amides, HIV Infections drug therapy, Nevirapine therapeutic use, Nevirapine administration & dosage, Methadone therapeutic use, Methadone administration & dosage, Heterocyclic Compounds, 4 or More Rings therapeutic use, Heterocyclic Compounds, 4 or More Rings administration & dosage, Anti-HIV Agents therapeutic use, Anti-HIV Agents administration & dosage, Heterocyclic Compounds, 3-Ring therapeutic use, Heterocyclic Compounds, 3-Ring administration & dosage
- Published
- 2024
- Full Text
- View/download PDF
3. Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
- Author
-
Clemente T, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fiscon M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, and Spagnuolo V
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Treatment Failure, Adult, Registries, HIV-1 drug effects, HIV-1 genetics, HIV Infections drug therapy, HIV Infections virology, Anti-HIV Agents therapeutic use, Anti-HIV Agents pharmacology, Viral Load drug effects, Drug Resistance, Viral
- Published
- 2024
- Full Text
- View/download PDF
4. Breakthrough Acute HIV Infections among Pre-Exposure Prophylaxis Users with High Adherence: A Narrative Review.
- Author
-
Moschese D, Lazzarin S, Colombo ML, Caruso F, Giacomelli A, Antinori S, and Gori A
- Subjects
- Humans, Pre-Exposure Prophylaxis, HIV Infections prevention & control, Anti-HIV Agents therapeutic use, Medication Adherence
- Abstract
Pre-exposure prophylaxis (PrEP) is a pivotal intervention among HIV prevention strategies. We aimed to narratively revise the topic of HIV acute infection in the setting of PrEP exposure with a focus on diagnostic options, clinical features, and future PrEP perspectives, with a particular focus on users with high adherence to PrEP. We searched the main databases (PubMed, Embase, and Scopus) with the keywords "PrEP" or "Pre-Exposure Prophylaxis" and "HIV" or "PLWH" and "breakthrough" or "acute infection" or "primary infection". We included all randomized clinical trials and non-experimental studies (both case reports and observational studies) ever published. In the present narrative review, we revise the diagnostic challenges related to HIV diagnosis in the setting of PrEP and the clinical characteristics and symptoms of breakthrough infections. We discuss the management of acute HIV infection during PrEP and the new challenges that arise from the use of long-acting drugs for PrEP. Our review underlines that although extremely rare, HIV seroconversions are still possible during PrEP, even in a context of high adherence. Efforts to promptly identify these events must be included in the PrEP follow-up in order to minimize the chance of overlooked HIV breakthrough infections and thus exposure to suboptimal concentrations of antiretrovirals.
- Published
- 2024
- Full Text
- View/download PDF
5. Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort.
- Author
-
Iannone V, Ciccullo A, Moschese D, Giacomelli A, Fabbiani M, Lagi F, Papalini C, De Vito A, Cossu MV, Di Giambenedetto S, and Borghetti A
- Subjects
- Humans, Italy, Male, Female, Middle Aged, Adult, Outpatients, Cost Savings, Cohort Studies, Tenofovir therapeutic use, HIV Infections drug therapy, Anti-HIV Agents therapeutic use, Anti-HIV Agents economics
- Published
- 2024
- Full Text
- View/download PDF
6. Effect of Carbamazepine on Darunavir Trough Concentrations: When the Dose Can Make the Difference-A Case Study.
- Author
-
Cattaneo D, Caloni B, Caronni S, Calvagna N, Bonini I, Giacomelli A, and Gervasoni C
- Subjects
- Humans, Male, Middle Aged, Trigeminal Neuralgia drug therapy, Ritonavir therapeutic use, Ritonavir administration & dosage, Anticonvulsants pharmacokinetics, Anticonvulsants therapeutic use, Anticonvulsants administration & dosage, Pyridones pharmacokinetics, Pyridones therapeutic use, Pyridones blood, Heterocyclic Compounds, 3-Ring pharmacokinetics, Heterocyclic Compounds, 3-Ring therapeutic use, Heterocyclic Compounds, 3-Ring administration & dosage, Piperazines therapeutic use, Piperazines pharmacokinetics, Oxazines therapeutic use, Oxazines pharmacokinetics, Dose-Response Relationship, Drug, Anti-HIV Agents therapeutic use, Anti-HIV Agents pharmacokinetics, Anti-HIV Agents administration & dosage, Drug Monitoring methods, Darunavir therapeutic use, Darunavir pharmacokinetics, Carbamazepine therapeutic use, Carbamazepine pharmacokinetics, Drug Interactions, HIV Infections drug therapy
- Abstract
Background: Carbamazepine (CBZ) is an antiseizure medication known to induce the expression of cytochrome P4503A metabolic enzymes. Here, we describe a man living with HIV who underwent several changes in the daily dose of CBZ, which resulted in different induction effects on darunavir trough concentrations., Methods: A 59-year-old man with HIV, successfully undergoing maintenance antiretroviral treatment with darunavir/cobicistat once daily (combined with raltegravir), was prescribed CBZ for recurrent trigeminal neuralgia. Over subsequent months, the patient underwent various changes in the doses (from 200 to 800 mg/d) and trough concentrations (from 3.6 to 18.0 mg/L) of CBZ, guided by clinical response to trigeminal neuralgia., Results: A highly significant inverse association was observed between darunavir trough concentration and both CBZ dose or trough concentration (coefficient of determination >0.75, P < 0.0001). Ultimately, the darunavir dose was increased to 600 mg twice daily with ritonavir and dolutegravir to ensure optimal antiretroviral coverage, anticipating potential further uptitration of CBZ doses., Conclusions: The impact of CBZ on boosted darunavir exposure seemed to be dose- and concentration-dependent. The management of such drug-drug interactions in daily practice was facilitated through therapeutic drug monitoring. This case underscores the importance of a multidisciplinary approach that incorporates both antiretroviral and nonantiretroviral comedications contributing to the optimal management of polypharmacy in individuals living with HIV., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
- Author
-
Cossu MV, Cattaneo D, Moschese D, Giacomelli A, Soloperto S, D'Avolio A, Antinori S, Gori A, Rizzardini G, and Gervasoni C
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Injections, Viral Load drug effects, Rilpivirine pharmacokinetics, Rilpivirine administration & dosage, Rilpivirine therapeutic use, Rilpivirine blood, HIV Infections drug therapy, Pyridones pharmacokinetics, Pyridones administration & dosage, Anti-HIV Agents pharmacokinetics, Anti-HIV Agents administration & dosage, Anti-HIV Agents blood, Anti-HIV Agents therapeutic use, Diketopiperazines
- Abstract
Objective: Large inter-individual variability in the pharmacokinetics of rilpivirine and cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) therapy. Here, we assessed the distribution of rilpivirine and cabotegravir trough concentrations in people with HIV (PWH) on long-term LAI treatment., Methods: Adult PWH treated with LAI for at least 32 weeks with an assessment of drug plasma trough concentrations were considered. The proportion of rilpivirine and cabotegravir plasma trough concentrations below four-times the protein-adjusted concentrations required for 90% inhibition of viral replication (4×PA-IC90) was estimated., Results: Sixty-seven PWH were identified. LAI treatment duration was 216 ± 80 weeks (range 32-320 weeks). Cabotegravir concentrations were associated with lower inter-individual variability compared with rilpivirine (45% versus 84%; P < 0.05). No differences were found in rilpivirine (160 ± 118 versus 189 ± 81 ng/mL; P = 0.430) and cabotegravir (1758 ± 807 versus 1969 ± 802 ng/mL; P = 0.416) trough concentrations in males (n = 55) versus females (n = 12). A non-significant trend for lower cabotegravir concentrations was found in PWH with a body mass index >30 kg/m2 (n = 9) versus non-obese participants (1916 ± 905 versus 1606 ± 576 ng/mL; P = 0.131). Three out of the 67 PWH had at least one drug concentration <4×PA-IC90: 100% of PWH had undetectable HIV viral load., Conclusions: At steady state, optimal systemic exposure of cabotegravir and rilpivirine was found in most PWH; cabotegravir trough concentrations were associated with lower inter-individual variability compared with rilpivirine. The study was not powered to assess the contribution of sex and/or body weight on LAI exposure due to the small number of females and obese PWH included., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
8. Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
- Author
-
Cossu MV, D'Avolio A, Gervasoni C, Giacomelli A, Cattaneo D, and Moschese D
- Subjects
- Humans, Injections, Intramuscular, Male, Female, Middle Aged, Adult, Rilpivirine therapeutic use, Rilpivirine pharmacokinetics, Rilpivirine administration & dosage, HIV Infections drug therapy, Pyridones pharmacokinetics, Pyridones administration & dosage, Pyridones therapeutic use, Anti-HIV Agents pharmacokinetics, Anti-HIV Agents therapeutic use, Anti-HIV Agents administration & dosage, Diketopiperazines
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
9. Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis - results from the ICONA cohort in Italy, 2009-2022.
- Author
-
Mondi A, Cozzi-Lepri A, Tavelli A, Cingolani A, Giacomelli A, Orofino G, De Girolamo G, Pinnetti C, Gori A, Saracino A, Bandera A, Marchetti G, Girardi E, Mussini C, d'Arminio Monforte A, and Antinori A
- Subjects
- Humans, CD4 Lymphocyte Count, Anti-Retroviral Agents therapeutic use, Italy epidemiology, Acquired Immunodeficiency Syndrome complications, Acquired Immunodeficiency Syndrome diagnosis, Acquired Immunodeficiency Syndrome drug therapy, HIV Infections complications, HIV Infections diagnosis, HIV Infections drug therapy, Anti-HIV Agents therapeutic use
- Abstract
Objectives: Limited data are available on the long-term outcomes in recent years for late HIV diagnosis (LD)., Methods: All subjects with HIV enrolled in the ICONA cohort in 2009-2022 who started antiretroviral treatment (ART) within 4 months from diagnosis were included and divided into: (i) pre-ART CD4 count ≥350/mm
3 without AIDS (non-LD), (ii) pre-ART CD4 count <350/mm3 without AIDS (LD asymptomatic), and (iii) with AIDS events pre-ART (LD-AIDS). The estimated probability and independent risk for mortality (all-cause and cause-specific) and treatment failure were evaluated., Results: Of 6813 participants (2448 non-LD, 3198 LD asymptomatic, and 1167 LD-AIDS), 161 (2.4%) died after ART initiation. At survival analysis, a higher probability of all-cause mortality has been identified for LD than non-LD (P <0.001) and within the former, for LD-AIDS over LD asymptomatic (P <0.001). After adjusting for confounders, LD showed a higher risk of all-cause mortality (vs non-LD adjusted hazard ratio (aHR) 5.51, P <0.001) and, in particular, being an AIDS presenter predicted a greater risk of all-cause (aHR = 4.42, P <0.001), AIDS-related (adjusted subhazard ratio [aSHR] = 16.86, P <0.001), and non-AIDS-related mortality (aSHR = 1.74, P = 0.022) than the rest of the late presenters. Among the short-term survivors in the LD-AIDS group, the long-term mortality was mediated by the lack of immune recovery at 2 years. Finally, LD compared with non-LD and, particularly, among the former, LD-AIDS over LD asymptomatic showed a greater risk of treatment failure., Conclusions: In recent years, LD subjects, particularly, AIDS presenters, remained at a higher risk of poorer outcomes. Public health strategies for early HIV diagnosis are urgently needed to constrain the mortality gap., Competing Interests: Declarations of competing interest A.M. received speaker honoraria from Gilead Sciences and ViiV Healthcare and travel fees and participated in advisory boards sponsored by ViiV Healthcare. A.C. received funding for scientific advisory boards, travel, or speaker honoraria from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, and MSD. A. Giacomelli reports speaker honoraria for ViiV Healthcare and Gilead Sciences and is an adviser for Janssen-Cilag and Mylan. C.P. received personal fees from Gilead Sciences for a case presentation and a travel grant and has served on an advisory board for Janssen-Cilag; A. Gori received speaker honoraria and fees for attending advisory boards from ViiV Healthcare, Gilead Sciences, Janssen-Cilag, MSD, BMS, Pfizer, and Novartis and received research grants from ViiV, BMS, and Gilead Sciences. A.S. received speaker honoraria or participated in advisory boards sponsored by Gilead Sciences, ViiV Healthcare, MSD, and Janssen-Cilag. A.B. received speaker honoraria and fees for attending advisory boards from Astra-Zeneca, BioMerieux, Janssen-Cilag, Nordic Pharma, Pfizer, Qiagen, SOBI, and ViiV and received research grants from Gilead; G.M. participated in the advisory boards of Gilead Sciences, ViiV Healthcare, Angelini, and Janssen-Cilag and received travel grants from ViiV Healthcare, MSD, and Janssen-Cilag; E.G. received grant support from Gilead Sciences and Mylan and speaker honoraria from Gilead Sciences. C.M. received speaker honoraria or participated in advisory boards sponsored by Gilead Sciences, ViiV Healthcare, MSD, and Janssen-Cilag and received research grants from Gilead Sciences; A.d.M. participated in advisory board of Gilead Sciences, ViiV Healthcare, MSD, Pfizer, and GSK and received research grant from Gilead Science, ViiV Healthcare, Merck Sharp and Dohme, GSK, and Janssen-Cilag; A.A. received research grants from Gilead Sciences, AstraZeneca, and ViiV Healthcare and honoraria from Gilead Science, AstraZeneca, GSK, Pfizer, MSD, Moderna, Mylan, Janssen-Cilag, and ViiV Healthcare; A.C-L., A.T., G.D.G., and G.O. have no competing interest to declare., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
10. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations.
- Author
-
Cattaneo D, Pagano S, Colombo ML, Giacomelli A, Gori A, and Gervasoni C
- Subjects
- Humans, Darunavir therapeutic use, Pharmaceutical Preparations, Heterocyclic Compounds, 3-Ring therapeutic use, Oxazines therapeutic use, Pyridones therapeutic use, Rilpivirine therapeutic use, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, Piperazines
- Abstract
Background: Dolutegravir is widely used in different dual and triple antiretroviral regimens. Here, we sought to investigate the effect of the companion antiretroviral drug(s) on dolutegravir plasma trough concentrations in persons with HIV, with a focus on dual regimens., Methods: Dolutegravir concentrations collected from October 2015 to March 2023 ( n = 900) were stratified according to the main antiretroviral classes (NRTIs, NNRTIs, protease inhibitors) and according to single drugs. Dolutegravir concentrations measured in persons with HIV concomitantly treated with lamivudine were considered as the reference group., Results: Dolutegravir trough concentrations were significantly higher in persons with HIV given protease inhibitors compared with the reference [1886 (1036-2940) versus 1575 (1026-2226) ng/ml; P = 0.004]. The highest dolutegravir concentrations were measured in persons with HIV concomitantly treated with unboosted atazanavir [2908 (2130-4135) ng/ml]. Conversely, co-administration of darunavir/ritonavir resulted in significantly lower dolutegravir exposure [909 (496-1397) ng/ml; P = 0.002 versus reference]. Among NNRTIs, the higher dolutegravir concentrations were measured in presence of rilpivirine [2252 (1489-2686); P < 0.001 versus reference]., Conclusion: Dolutegravir trough concentrations are differently affected by individual antiretroviral drugs, with some drug combinations (i.e. dolutegravir/darunavir/cobicistat, or dolutegravir/rilpivirine) providing significantly higher than expected dolutegravir exposure. Such combinations might be advantageous when there are concerns about dolutegravir plasma exposure or resistance., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Management of the Drug-Drug Interactions Between Valproic Acid and Dolutegravir-A Case Study.
- Author
-
Cattaneo D, Giacomelli A, Calvagna N, Bonini I, Ridolfo AL, and Gervasoni C
- Subjects
- Humans, Male, Middle Aged, HIV Integrase Inhibitors therapeutic use, HIV Integrase Inhibitors pharmacokinetics, Anti-HIV Agents therapeutic use, Anti-HIV Agents pharmacokinetics, Heterocyclic Compounds, 3-Ring pharmacokinetics, Heterocyclic Compounds, 3-Ring therapeutic use, Pyridones therapeutic use, Pyridones pharmacokinetics, Piperazines therapeutic use, Drug Interactions, Oxazines, Valproic Acid therapeutic use, HIV Infections drug therapy, Drug Monitoring methods
- Abstract
Objective: Preliminary evidence shows that concomitant administration of valproic acid can reduce the exposure to dolutegravir with limited clinical impacts. Here, we describe a male living with HIV who experienced a drastic reduction in dolutegravir trough concentrations a few weeks after starting valproic acid treatment as identified by therapeutic drug monitoring. Concomitantly, pharmacists recommended a supplementation of magnesium to improve insomnia., Case Report: A 62-year-old man with HIV on antiretroviral therapy with dolutegravir and lamivudine recently added valproic acid to clonazepam and sertraline to treat severe sleep disturbances. An 84% reduction in dolutegravir trough concentrations was observed compared with the previous outpatient visit (418 versus 2714 ng/mL), with values close to the minimum effective drug concentration (300 ng/mL). Considering this, we strongly discourage the use of magnesium., Conclusions: We are confident that our findings can contribute to a better understanding of the clinical problems that infectious disease physicians encounter in their daily management of people with HIV and how therapeutic drug monitoring may add value in this context. This case also highlights the importance of multidisciplinary services for the optimal management of polypharmacy in people with HIV., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort.
- Author
-
Gagliardini R, Giacomelli A, Bozzi G, D'Arminio Monforte A, Tavelli A, Mazzotta V, Bruzzesi E, Cervo A, Saracino A, Mussini C, Girardi E, Cozzi-Lepri A, and Antinori A
- Subjects
- Humans, Pandemics, Transients and Migrants, HIV Infections epidemiology, Retention in Care, COVID-19 epidemiology
- Abstract
Background: COVID-19 pandemic challenged the UNAIDS 90-90-90 targets. How the COVID-19 pandemic affected HIV retention in care and whether it has disproportionally affected migrant people with HIV (PWH) remained to be investigated., Methods: PWH in ICONA Cohort in follow-up in each of the study periods were included: 01/09/2019-29/02/2020 (pandemic period) and 01/03/2018-31/08/2018 (historical period, as a control). Risk of temporary loss to follow-up (LTFU, defined as no data recorded for a person for one year) was analyzed by logistic regression, with migrant status as the main exposure variable. Difference in difference (DID) analysis was applied to evaluate the effect of COVID-19 pandemic in the different risk of LTFU between natives and migrants., Results: 8864 (17.1% migrants) and 8071 (16.8% migrants) PWH constituted the pandemic and the historical period population, respectively. Proportion of PWH defined as LTFU in the pandemic period was 10.5% in native and 19.6% in migrant PWH. After controlling for age, sex and geographical location of enrolling site, risk of temporary LTFU was higher for migrants than native PWH [adjusted odds ratio 1.85 (95%CI 1.54-2.22)] in pandemic period. In PWH contributing to both periods, LTFU was 9.0% (95% CI 8.3-9.8) in natives vs 17.0% (95% CI 14.7-19.4) in migrants during the pandemic. Instead, LTFU was 1.2% (95%CI 0.9, 1.5) in natives vs 2.2% (95% CI 1.3-3.1) in migrants during the historical period, with a resulting DID of 7.0% (95% CI 4.4-9.6)., Conclusions: A greater proportion of LTFU in migrant PWH was observed in both periods, which remained unaltered over time. Interventions to reduce LTFU of migrants are necessary., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Roberta Gagliardini reports payments to her institution from Gilead Sciences, speakers’ honoraria/educational activities for ViiV Healthcare, Merck Sharp and Dohme and Gilead Sciences, advisor for Theratechnologies, Janssen-Cilag and Gilead Sciences. Andrea Giacomelli received consultancy fees from Mylan and Janssen. Speaker honoraria from ViiV, Gilead, and MSD. Educational and grant support from Gilead and ViiV. Antonella D'arminio Monforte is a consultant or participated in advisory boards sponsored by Gilead Sciences, ViiV Healthcare, Janssen-Cilag, GSK, Merck Sharp & Dohme and received research grants from Gilead Sciences and ViiV Healthcare. Enrico Girardi received research grants from Gilead and Mylan and speaker fees from Gilead and ViiV unrelated to the present study. All other authors report no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
- Author
-
Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, Giacomelli A, Torti C, Sterrantino G, Mussini C, Antinori S, and Di Giambenedetto S
- Subjects
- Humans, Emtricitabine therapeutic use, Pyridones therapeutic use, Heterocyclic Compounds, 4 or More Rings adverse effects, Fumarates therapeutic use, HIV Infections drug therapy, Anti-HIV Agents adverse effects, Adenine analogs & derivatives, Tenofovir analogs & derivatives, Alanine, Oxazines, Heterocyclic Compounds, 3-Ring, Amides, Piperazines
- Abstract
Background: First-line integrase strand transfer inhibitor-based regimens have become commonly used in clinical practice over the last decade. This study aimed to analyse and compare the efficacy and safety of bictegravir (BIC) and dolutegravir (DTG) when prescribed in association with emtricitabine/tenofovir alafenamide (FTC/TAF) as part of a first-line regimen for the treatment of human immunodeficiency-1 (HIV-1) infection., Methods: Treatment-naïve people living with HIV (PLWHIV) starting a first-line regimen with either BIC/FTC/TAF (BIC group) or FTC/TAF+DTG (DTG group) were analysed. Snapshot analyses were performed after 24 and 48 weeks to evaluate virological efficacy. In addition, differences in the rate of treatment discontinuation (TD) between the two groups were evaluated using the Kaplan-Meier method and the log rank test., Results: Data from 327 PLWHIV were analysed: 140 in the DTG group and 187 in the BIC group. At 48 weeks, 90.0% of individuals in the DTG group and 86.7% of those in the BIC group achieved HIV-RNA <50 copies/mL. In total, 88 and 38 cases of TD were observed in the DTG group and BIC group, respectively. The estimated probability of maintaining the study regimen at week 48 was 59.5% in the DTG group and 84.2% in the BIC group. Analysing changes in immunological parameters after 48 weeks, median improvements of +169 cell/mm
3 (P<0.001) and +233 cell/mm3 (P<0.001) were observed in the DTG group and the BIC group, respectively., Conclusions: Both BIC and DTG, in combination with FTC/TAF, show promising efficacy and safety as first-line strategies in clinical practice, with favourable immunological recovery even in the short term., (Copyright © 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
14. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort.
- Author
-
Gagliardini R, Tavelli A, Rusconi S, Lo Caputo S, Spagnuolo V, Santoro MM, Costantini A, Vergori A, Maggiolo F, Giacomelli A, Burastero G, Madeddu G, Quiros Roldan E, d'Arminio Monforte A, Antinori A, and Cozzi-Lepri A
- Subjects
- Humans, Treatment Failure, Survival Analysis, Viral Load, Anti-HIV Agents adverse effects, Acquired Immunodeficiency Syndrome drug therapy, HIV Infections drug therapy, HIV Infections epidemiology
- Abstract
Objectives: Treatment failures to modern antiretroviral therapy (ART) raise concerns, as they could reduce future options. Evaluations of occurrence of multiple failures to modern ART are missing and their significance in the long run is unclear., Methods: People with HIV (PWH) in the ICONA cohort who started a modern first-line ART were defined as 'difficult to treat' (DTT) if they experienced ≥1 among: i) ≥2 VF (2 viral loads, VL>200 copies/mL or 1 VL>1000 copies/mL) with or without ART change; ii) ≥2 treatment discontinuations (TD) due to toxicity/intolerance/failure; iii) ≥1 VF followed by ART change plus ≥1 TD due to toxicity/intolerance/failure. A subgroup of the DTT participants were matched to PWH that, after the same time, were non-DTT. Treatment response, analysing VF, TD, treatment failure, AIDS/death, and SNAE (Serious non-AIDS event)/death, were compared. Survival analysis by KM curves and Cox regression models were employed., Results: Among 8061 PWH, 320 (4%) became DTT. Estimates of becoming DTT was 6.5% (95% CI: 5.8-7.4%) by 6 years. DTT PWH were significantly older, with a higher prevalence of AIDS and lower CD4+ at nadir than the non-DTT. In the prospective analysis, DTT demonstrated a higher unadjusted risk for all the outcomes. Once controlled for confounders, significant associations were confirmed for VF (aHR 2.23, 1.33-3.73), treatment failure (aHR 1.70, 1.03-2.78), and SNAE/death (aHR 2.79, 1.18-6.61)., Conclusion: A total of 6.5% of PWH satisfied our definition of DTT by 6 years from ART starting. This appears to be a more fragile group who may have higher risk of failure., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
- Author
-
Giacomelli A, Cossu MV, Moschese D, and Gervasoni C
- Subjects
- Humans, Anti-Retroviral Agents therapeutic use, Pyridones therapeutic use, Lamivudine therapeutic use, HIV Infections drug therapy
- Published
- 2023
- Full Text
- View/download PDF
16. Delayed diagnosis among patients with visceral leishmaniasis.
- Author
-
Poloni A, Giacomelli A, Corbellino M, Grande R, Nebuloni M, Rizzardini G, Ridolfo AL, and Antinori S
- Subjects
- Adult, Female, Humans, Male, Delayed Diagnosis, Immunosuppression Therapy, Retrospective Studies, Middle Aged, Coinfection drug therapy, HIV Infections, Leishmaniasis, Visceral diagnosis, Leishmaniasis, Visceral drug therapy, Leishmaniasis, Visceral epidemiology
- Abstract
We aimed to estimate the diagnostic latency of patients with visceral leishmaniasis (VL). A monocentric retrospective observational study was conducted including all confirmed cases of VL diagnosed from January 2005 to March 2022. Epidemiological and clinical characteristics of patients with VL were collected. The diagnostic latency was defined as the number of days between the first contact with a health-care provider for signs and/or symptoms referable to VL and the laboratory diagnosis of leishmaniasis. Twenty-four cases of VL were included in the study, mostly male (75%) and Italians (79.2%), with a median age of 40 years [Inter Quartile Range (IQR 30-48)]. Fourteen (58.3%) VL cases were people living with HIV (PLWH) and 4 (16.6%) subjects were on immunosuppressive therapy. For VL the median diagnostic latency was 54 days (IQR 28-162). The shorter diagnostic latency was observed in PLWH [31 days (IQR 20-47)] followed by immunocompetent patients [160 days (IQR 133-247)] and those on immunosuppressive therapy [329 days (IQR 200-678)]. Twelve patients (50%) reported at least one medical encounter before the diagnosis of VL and 6 patients received a wrong therapy. Diagnostic delay in VL was significant in patients under immune suppressive treatment., (© 2023. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).)
- Published
- 2023
- Full Text
- View/download PDF
17. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network.
- Author
-
Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, Mondi A, Augello M, Antinori S, Vergori A, Gori A, Menozzi M, Taramasso L, Fusco FM, De Vito A, Mancarella G, Marchetti G, D'Arminio Monforte A, Antinori A, and Cozzi-Lepri A
- Subjects
- Humans, Hospital Mortality, Retrospective Studies, SARS-CoV-2, COVID-19, HIV Infections complications, HIV Infections epidemiology
- Abstract
Objectives: We aimed to study whether people living with HIV (PLWH) are at higher risk of in-hospital COVID-19 mortality compared to the general population (GenPop)., Methods: This was a retrospective study in 19 Italian centers (February 2020 to November 2022) including hospitalized PLWH and GenPop with SARS-CoV-2 infection. The main outcome was in-hospital mortality. Competing risk analyses by Fine-Gray regression model were used to estimate the association between in-hospital mortality and HIV status/age., Results: A total of 7399 patients with COVID-19 were included, 239 (3.2%) PLWH, and 7160 (96.8%) GenPop. By day 40, in-hospital death occurred in 1283/7160 (17.9%) among GenPop and 34/239 (14.2%) among PLWH. After adjusting for potential confounders, compared to GenPop <65 years, a significantly higher risk of death was observed for GenPop ≥65 (adjusted subdistribution hazard ratio [aSHR] 1.79 [95% CI 1.39-2.31]), PLWH ≥65 (aSHR 2.16 [95% CI 1.15-4.04]), PLWH <65 with CD4 ≤200 (aSHR 9.69 [95% CI 5.50-17.07]) and PLWH <65 with CD4 201-350 (aSHR 4.37 [95% CI 1.79-10.63]), whereas no evidence for a difference for PLWH <65 with CD4 >350 (aSHR 1.11 [95% CI 0.41-2.99])., Conclusions: In PLWH aged <65 years a CD4 ≤350 rather than HIV itself seems the driver for the observed higher risk of in-hospital mortality. We cannot however rule out that HIV infection per se is the risk factor in those aged ≥65 years., Competing Interests: Declarations of competing interest A Giacomelli reports speakers’ honoraria for ViiV Healthcare and Gilead Sciences, advisor for Janssen-Cilag and Mylan; RG reports payments to her institution from Gilead Sciences, speakers’ honoraria for ViiV Healthcare, Merck Sharp and Dohme and Gilead Sciences, advisor for Thera Technologies, Janssen-Cilag and Gilead Sciences; GR reports consultancies/advisory from ViiV Healthcare, GSK, Merck Sharp and Dohme and Gilead Sciences; A Gori received speaker's honoraria and fees for attending advisory boards from ViiVHealthcare, Gilead, Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer and Novartis and received research grants from ViiV, Bristol-Myers Squibb, and Gilead; AM received speakers’ honoraria from Gilead Sciences, and ViiV Healthcare, travel fee from Viiv Healthcare and participated in advisory boards sponsored by ViiV Healthcare; AV received an institutional grant from Gilead Sciences, speakers’ honoraria/educational activities from Merck Sharp & Dohme and Janssen-Cilag, and served an advisor for Janssen-Cilag; MM received speakers’ honoraria from ViiV Healthcare; LT reports consultancies/advisory from Viiv Healthcare, Gilead Sciences and Janssen-Cilag and institutional fellowship from Gilead Sciences; G Marchetti participated to advisory boards of Gilead Sciences, ViiV Healthcare, Angelini and Janssen-Cilag, and received travel grants from ViiV Healthcare and Janssen-Cilag; AdM participated in advisory board of Gilead Sciences, ViiV Healthcare, Merck Sharp and Dohme, Pfizer and GSK and reports research grant from Gilead Science, ViiV Healthcare, Merck Sharp and Dohme, GSK and Janssen-Cilag; AA received Research grants from Gilead Sciences, AstraZeneca, ViiV Healthcare and Honoraria from Gilead Science, AstraZeneca, GSK, Pfizer, Merck Sharp and Dohme, Moderna, Mylan, Janssen-Cilag, ViiV Healthcare; AT, SDB, SA, G Mancarella, FMF, ADV, VM, MA and ACL have nothing to declare., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
- Author
-
Lagi F, Giacomelli A, Borghi V, Ciccullo A, Taramasso L, Madeddu G, D'Ettorre G, Giacometti A, Ducci F, De Vito A, Pincino R, Di Giambenedetto S, Mussini C, Antinori S, and Sterrantino G
- Subjects
- Humans, Lamivudine adverse effects, Reverse Transcriptase Inhibitors adverse effects, Retrospective Studies, Rilpivirine adverse effects, Heterocyclic Compounds, 3-Ring adverse effects, Anti-HIV Agents adverse effects, HIV Infections drug therapy
- Abstract
Real-life comparisons of dolutegravir/rilpivirine (DTG/RPV) and DTG/lamivudine (3TC) regimens in people living with human immunodeficiency virus (PLWHIV) who switched from a standard three-drug regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTIs) are missing. This study aimed to compare DTG/3TC and DTG/RPV in virologically suppressed patients (HIV-RNA < 50 copies/mL) coming from any NNRTI-based regimen in terms of discontinuation due to virologic failure (VF) discontinuation rates due to all causes, and adverse events. As a secondary outcome, we evaluated the difference in creatinine, total cholesterol, CD4, and triglycerides from baseline to weeks 48 after the switch. Of the 415 PLWHs included in the study, 278 (66.9%) switched to DTG/3TC, and 137 (33.1%) switched to DTG/RPV. Overall, 48 PLWHs (11.6%) discontinued the treatment:38 with DTG/3TC and 10 with DTG/RPV with similar discontinuation rates: 5.01 × 100 py (95% confidence interval [CI] 3.64-6.94) and 4.66 × 100 py (95% CI 2.51-8.67), respectively. The most common reason for discontinuation was toxicity (26 patients, 22/278 [7.9%] in the DTG/3TC group and 4/137 [2.9%] in the DTG/RPV group), mainly neurologic toxicity (never above grade 2). We found no differences in discontinuation rates due to treatment adverse events. Two study participants experienced virological failure in the DTG/3TC arm. We observed no significant difference in CD4 cell counts, lipid parameters, or renal function between the two groups at 48 weeks. This study demonstrated that, in clinical practice, a two-drug regimen with DTG/3TC or DTG/RPV is characterized by a low discontinuation rate and VF in virologically suppressed PLWHs switched from an NNRTI-based three antiretroviral drugs regimen., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
19. Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy.
- Author
-
Bozzi G, Fabeni L, Abbate I, Berno G, Muscatello A, Taramasso L, Fabbiani M, Nozza S, Tambussi G, Rusconi S, Giacomelli A, Focà E, Pinnetti C, d'Ettorre G, Mussini C, Borghi V, Celesia BM, Madeddu G, Di Biagio A, Ripamonti D, Squillace N, Antinori A, Gori A, Capobianchi MR, and Bandera A
- Subjects
- Male, Humans, Adult, Female, Phylogeny, Bayes Theorem, Italy epidemiology, RNA, Genotype, Molecular Epidemiology, Cluster Analysis, HIV-1 genetics, HIV Infections epidemiology, HIV Seropositivity
- Abstract
Objectives and Design: Using pol sequences obtained for routine resistance testing, we characterised the molecular patterns of HIV-1 transmission and factors associated with being part of a transmission cluster among individuals who in 2008-2014 presented with primary HIV-1 infection (PHI) at 11 urban centres across Italy., Methods: Pol sequences were obtained by Sanger sequencing. Transmission clusters were identified by phylogenetic analysis (maximum likelihood method, confirmed by Bayesian analysis). Multivariable logistic regression explored factors associated with a participant being part of a transmission cluster., Results: The PHI cohort comprised 186 participants (159/186, 85.5% males) with median age 44 years, median CD4 count 464 cells/mm
3 and median plasma HIV-1 RNA 5.6 log10 copies/mL. Drug resistance associated mutations were found in 16/186 (8.6%). A diversity of non-B subtypes accounted for 60/186 (32.3%) of all infections. A total of 17 transmission clusters were identified, including 44/186 (23.7%) participants. Each cluster comprised 2-6 sequences. Non-B subtypes accounted for seven clusters and 22/44 (50%) of clustered sequences. In multivariable logistic regression analysis, factors associated with being part of a transmission cluster comprised harbouring a non-B subtype (adjusted OR (adjOR) 2.28; 95% CI 1.03 to 5.05; p=0.04) and showing a lower plasma HIV-1 RNA (adjOR 0.80, 95% CI 0.64 to 0.99; p=0.04)., Conclusions: There was a large contribution of diverse non-B subtypes to transmission clusters among people presenting with acute or recent HIV-1 infection in this cohort, illustrating the evolving dynamics of the HIV-1 epidemic in Italy, where subtype B previously dominated., Competing Interests: Competing interests: LT reports past (within 36 months) financial relationships (advisory board membership or consultancy fees, speakers’ honoraria or travel support) with Gilead Sciences, Janssen, Viiv Healthcare and no other conflict of interest. MF reports past (within 36 months) financial relationships (advisory board membership or consultancy fees, speakers’ honoraria or travel support) with Gilead Sciences, Janssen, Viiv Healthcare, BMS, MSD and no other conflict of interest. SR reports past (within 36 months) financial relationships (advisory board membership or consultancy fees, speakers’ honoraria or travel support) with Gilead Sciences, Janssen, Viiv Healthcare and no other conflict of interest. AG reports past (within 36 months) financial relationships (educational support) with Mylan and no other conflict of interest. EF reports past (within 36 months) financial relationships (advisory board membership or consultancy fees, speakers’ honoraria or travel support) with Gilead Sciences, Janssen, Viiv Healthcare, MSD and no other conflict of interest. CP reports past (within 36 months) financial relationships (advisory board membership or consultancy fees, speakers’ honoraria or travel support) with Janssen. GM reports past (within 36 months) financial relationships (advisory board membership or consultancy fees, speakers’ honoraria or travel support) with Gilead Sciences, Janssen, Viiv Healthcare, MSD and no other conflict of interest. AG reports past (within 36 months) grant/research supports, honoraria or consultation fees, speaker’s bureau compensation and/or travel support from Abbvie, Astellas, BMS, Boeringher, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, ViiV and no other conflict of interest., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
20. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review.
- Author
-
Jordans CCE, Vasylyev M, Rae C, Jakobsen ML, Vassilenko A, Dauby N, Grevsen AL, Jakobsen SF, Raahauge A, Champenois K, Papot E, Malin JJ, Boender TS, Behrens GMN, Gruell H, Neumann A, Spinner CD, Valbert F, Akinosoglou K, Kostaki EG, Nozza S, Giacomelli A, Lapadula G, Mazzitelli M, Torti C, Matulionyte R, Matulyte E, Van Welzen BJ, Hensley KS, Thompson M, Ankiersztejn-Bartczak M, Skrzat-Klapaczyńska A, Săndulescu O, Streinu-Cercel A, Streinu-Cercel A, Miron VD, Pokrovskaya A, Hachfeld A, Dorokhina A, Sukach M, Lord E, Sullivan AK, and Rokx C
- Subjects
- Female, Pregnancy, Humans, Europe epidemiology, Europe, Eastern, HIV Testing, HIV Infections diagnosis, HIV Infections epidemiology, Medicine
- Abstract
BackgroundAdequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing.AimTo evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries.MethodsBetween 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90-90-90 goals and medical specialty).ResultsOf 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90-90-90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines.ConclusionFewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.
- Published
- 2022
- Full Text
- View/download PDF
21. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
- Author
-
Saumoy M, Sánchez-Quesada JL, Assoumou L, Gatell JM, González-Cordón A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masiá M, Ordónez-Llanos J, Pozniak A, Martínez E, and Podzamczer D
- Subjects
- 1-Alkyl-2-acetylglycerophosphocholine Esterase therapeutic use, Female, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Piperazines, Protease Inhibitors therapeutic use, Pyridones, Anti-HIV Agents therapeutic use, Atherosclerosis, HIV Infections drug therapy, Lipoproteins, LDL metabolism
- Abstract
Background: The aim of this study was to investigate whether switching from a ritonavir-boosted PI-based regimen to a dolutegravir-based regimen improved the atherogenic properties of LDL particles in patients with HIV., Methods: This was a substudy of the NEAT022 study (ClinicalTrials.gov NCT02098837). Adults with HIV with a Framingham score >10% or aged >50 years and being treated with a stable boosted PI-based regimen were randomized to either switch to dolutegravir or continue with boosted PI. At baseline and Week 48, we assessed atherogenic LDL properties: LDL particle size and phenotype (A, intermediate, B), oxidized LDL (ox-LDL) and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity., Results: Eighty-six participants (dolutegravir 44; PI 42) were included. Participants had a median (IQR) age of 54 (51-57) years and 79.1% were male. In the dolutegravir arm, after 48 weeks, we observed: (1) an increase in LDL size [median 1.65 Å (IQR -0.60 to 4.20); P = 0.007], correlated with the decrease in triglyceride concentration [Spearman correlation = -0.352 (P = 0.001)], with a corresponding decrease of subjects with atherogenic LDL phenotype B (36.4% to 20.5%; P = 0.039); (2) a decrease in Lp-PLA2 activity [median 1.39 μmol/min/mL (IQR -2.3 to 0.54); P = 0.002]; and (3) a decrease in ox-LDL [median 14 U/L (IQR -102 to 13); P = 0.006]. In the PI arm, none of these favourable lipid modifications was observed., Conclusions: Forty-eight weeks after switching from a PI-based to a dolutegravir-based regimen, patients with Framingham score >10% or aged >50 years showed improvement of several atherogenic lipid features, including LDL particle phenotype, ox-LDL and Lp-PLA2., (© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
22. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
- Author
-
Ciccullo A, Baldin G, Borghi V, Lagi F, Latini A, d'Ettorre G, Oreni L, Fusco P, Capetti A, Fabbiani M, Giacomelli A, Grimaldi A, Madeddu G, Sterrantino G, Mussini C, and Di Giambenedetto S
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Anti-HIV Agents toxicity, Cohort Studies, Female, HIV Infections epidemiology, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Italy epidemiology, Male, Middle Aged, Oxazines therapeutic use, Piperazines therapeutic use, Pyridones therapeutic use, Drug Tolerance, HIV Infections drug therapy, HIV Integrase Inhibitors toxicity, Heterocyclic Compounds, 3-Ring toxicity, Oxazines toxicity, Piperazines toxicity, Pyridones toxicity
- Abstract
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction.
- Published
- 2022
- Full Text
- View/download PDF
23. Liver Injury After Dietary Supplements in Patients Living With HIV: A Call to Action.
- Author
-
Cattaneo D, Giacomelli A, and Gervasoni C
- Subjects
- Dietary Supplements adverse effects, Humans, Chemical and Drug Induced Liver Injury, HIV Infections complications, HIV Infections drug therapy
- Published
- 2022
- Full Text
- View/download PDF
24. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
- Author
-
Ciccullo A, Borghi V, Giacomelli A, Cossu MV, Sterrantino G, Latini A, Giacometti A, De Vito A, Gennari W, Madeddu G, Capetti A, d'Ettorre G, Mussini C, Rusconi S, Di Giambenedetto S, and Baldin G
- Subjects
- Female, HIV Seropositivity drug therapy, Humans, Male, Middle Aged, RNA therapeutic use, Retrospective Studies, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Lamivudine therapeutic use, Oxazines therapeutic use, Piperazines therapeutic use, Pyridones therapeutic use
- Abstract
Background: Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1-positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort., Methods: This was a retrospective study enrolling HIV-1-infected, virologically suppressed patients switching to dolutegravir + lamivudine. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1000 copies/mL or by 2 consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (defined as the interruption of either 3TC or dolutegravir), assessing predictors via Cox regression analyses., Results: Seven-hundred eighty-five patients were considered for the analysis: 554 were men (70.6%), with a median age of 52 years (interquartile range 45-58 years). Estimated probabilities of maintaining virological suppression at weeks 96, 144, and 240 were 97.7% (SD ±0.6), 96.9% (SD ±0.8), and 96.4% (SD ±0.9), respectively. A non-B HIV subtype (P = 0.014) and a previous VF (P = 0.037) resulted predictors of VF. We did not observe differences in probability of VF in people living with HIV with an M184V resistance mutation (P = 0.689); however, in a deeper analysis, M184V mutation was a predictor of VF (P = 0.038) in patients with time of virological suppression <88 months. Estimated probabilities of remaining on study regimen at 96, 144, and 240 weeks were 82.9% (SD ±1.4), 79.7% (SD ±1.6) and 74.3% (SD ±2.2), respectively., Conclusions: Our findings show the long-term efficacy and tolerability of dolutegravir plus lamivudine in virologically suppressed patients., Competing Interests: A. Ciccullo received travel grants from ViiV Healthcare. A.G. reports grants and/or personal fees from BMS, Gliead, Janssen, MSD and ViiV Healthcare. A. Capetti has received a personal grant from AB, Gilead, and ViiV. G.S. has received funds for speaking by Gilead, Merck, Janssen, AbbVie, and ViiV. C.M. has participated in advisory boards and received study grants and/or speaker honoraria from AbbVie, Gilead, ViiV, Janssen, Angelini, BMS, and MSD. S.R. received research grants to his institution from ViiV Heathcare, Gilead Sciences, and Janssen, outside the submitted work; he was also a paid consultant for ViiV Heathcare, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, and Janssen. S.D.G. was a paid consultant or member of advisory boards for Gilead, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme, and Bristol-Myers Squibb. The remainig authors have no conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
25. Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic.
- Author
-
Giacomelli A, Bonazzetti C, Conti F, Pezzati L, Oreni L, Micheli V, Mancon A, Vimercati S, Albrecht M, Passerini M, Cossu MV, Capetti AF, Meraviglia P, Antinori S, Rizzardini G, Galli M, and Ridolfo AL
- Subjects
- Ambulatory Care Facilities, Anti-HIV Agents administration & dosage, Delivery of Health Care methods, HIV Infections drug therapy, HIV-1, Humans, Italy epidemiology, RNA, Viral blood, SARS-CoV-2, Viral Load drug effects, Anti-HIV Agents therapeutic use, COVID-19 complications, COVID-19 epidemiology, HIV Infections complications, HIV Infections epidemiology
- Abstract
Background: We assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on HIV suppression rates in people living with HIV (PLWH) attending a large Italian HIV clinic., Setting: The HIV outpatient clinic of the Infectious Diseases Department of Luigi Sacco Hospital, Milan, Italy, which serves more than 5000 PLWH per year., Methods: A before and after quasi-experimental study design was used to make a retrospective assessment of the monthly trend of HIV-RNA determinations of ≥50 among the PLWH attending our clinic, with "before" being the period from January 1, 2016 to February 20, 2020, and "after" being the period from February 21, 2020 to December 31, 2020 (the COVID-19 period). Interrupted time series analysis was used to evaluate any changes in the trend., Results: During the study period, 70,349 HIV-RNA viral load determinations were made, and the percentage of HIV-RNA viral load determinations of <50 copies/mL increased from 88.4% in 2016 to 93.2% in 2020 (P < 0.0001). There was a significant monthly trend toward a decrease in the number of HIV-RNA determinations of ≥50 copies/mL before the pandemic (β -0.084; standard error 0.015; P < 0.001), and this did not significantly change after it started (β -0.039, standard error 0.161; P = 0.811)., Conclusions: A high prevalence of viral suppression was maintained among the PLWH referring to our clinic, despite the structural barriers raised by the COVID-19 pandemic. The use of simplified methods of delivering care (such as teleconsultations and multiple antiretroviral treatment prescriptions) may have contributed to preserving this continuum., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience.
- Author
-
Mazzitelli M, Ciccullo A, Baldin G, Cauda R, Rusconi S, Giacomelli A, Oreni L, Borghi V, Mussini C, Guaraldi G, Sterrantino G, Lagi F, Candelaresi B, Cirioni O, De Vito A, Rossetti B, Torti C, and Di Giambenedetto S
- Subjects
- Adult, CD4 Lymphocyte Count statistics & numerical data, COVID-19 epidemiology, Cross-Sectional Studies, Female, HIV Infections diagnosis, Humans, Italy epidemiology, Male, Mass Screening organization & administration, Middle Aged, Pandemics, Retrospective Studies, Risk Factors, SARS-CoV-2, Delivery of Health Care organization & administration, HIV Infections epidemiology, Mass Screening statistics & numerical data
- Abstract
Abstract: The occurrence of COVID-19 pandemic had a significant negative effect on health care systems over the last year. Health care providers were forced to focus mainly on COVID-19 patients, neglecting in many cases equally important diseases, both acute and chronic. Therefore, also screening and diagnostic strategies for HIV could have been significantly impaired.This retrospective, multicenter, observational study aimed at assessing the number and characteristics of new HIV/AIDS diagnoses during COVID-19 pandemic in Italy and compared characteristics of people living with HIV at diagnosis between pre- and post-COVID-19 era (2019 vs 2020).Our results showed a significant reduction of HIV diagnoses during pandemic. By contrast, people living with HIV during pandemic were older and were diagnosed in earlier stage of disease (considering CD4+ T cell count) compared to those who were diagnosed the year before. Moreover, there was a significant decrease of new HIV diagnoses among men who have sex with men, probably for the impact of social distancing and restriction applied by the Italian Government. Late presentation incidence, if numbers in 2020 were lower than those in 2019, is still an issue.Routinely performing HIV testing in patients with suspected SARS-CoV-2 infection is identifying and linking to care underdiagnosed people living with HIV earlier. Thus, combined tests (HIV and SARS-CoV-2) should be implemented in patients with SARS-CoV-2 symptoms overlapping HIV's ones. Lastly, our results lastly showed how urgent implementation of a national policy for HIV screening is necessary., Competing Interests: The authors report no conflicts of interest., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
27. Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort.
- Author
-
Giacomelli A, Cozzi-Lepri A, Cingolani A, Tavelli A, Mazzotta V, Tesoro D, Bassetti M, Castagna A, Di Biagio A, Lichter M, Monforte AD, and Rusconi S
- Subjects
- Coinfection, HIV Infections complications, HIV Infections epidemiology, Humans, Italy epidemiology, RNA therapeutic use, Syphilis epidemiology, Viral Load, Antiretroviral Therapy, Highly Active methods, HIV Infections drug therapy, Syphilis complications
- Abstract
Background: To assess the impact of syphilis infection on the risk of HIV-RNA elevation in people living with HIV (PLWH) with current HIV-RNA ≤50 copies/mL., Setting: The Italian Cohort Naive Antiretrovirals., Methods: All PLWH (2009-2020) under antiretroviral treatment with at least 2 consecutive HIV-RNA values ≤50 copies/mL before the date of syphilis diagnosis and at least 1 HIV-RNA determination after the syphilis event were enrolled. A control group of PLWH without syphilis was matched for mode of HIV transmission. Outcomes were defined using the first HIV-RNA measure in the time window ranging between -2 and +6 months of the diagnosis/index date. The primary outcome used a single value >200 copies/mL to define HIV-RNA elevation associated with risk of transmission. The association between syphilis infection and the protocol defined outcome was evaluated using logistic regression analysis., Results: Nine hundred twenty-six PLWH with a syphilis event were enrolled and matched with a random sample of 1370 PLWH without syphilis. Eighteen of the 926 (1.9%) with syphilis had ≥1 HIV-RNA >200 copies/mL in the window vs. 29/1370 (2.1%) of the not exposed (P = 0.77). In the multivariable analysis adjusted for age, year of diagnosis/index date, and clinical site, syphilis infection was not associated with the risk of HIV-RNA >200 copies/mL (adjusted odds ratio 0.81; 95% confidence interval 0.43-1.52, P = 0.508)., Conclusions: We did not find any evidence for an association between syphilis infection and viral elevation >200 copies/mL., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
28. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
- Author
-
Giacomelli A, Conti F, Pezzati L, Oreni L, Ridolfo AL, Morena V, Bonazzetti C, Pagani G, Formenti T, Galli M, and Rusconi S
- Subjects
- Adult, Anti-HIV Agents metabolism, Body Weight drug effects, Cohort Studies, Dideoxynucleosides metabolism, Drug Combinations, Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination metabolism, Emtricitabine, Rilpivirine, Tenofovir Drug Combination metabolism, Female, Heart Disease Risk Factors, Heterocyclic Compounds, 3-Ring metabolism, Humans, Italy epidemiology, Lamivudine metabolism, Lipid Metabolism drug effects, Lipids blood, Male, Middle Aged, Oxazines metabolism, Piperazines metabolism, Pyridones metabolism, Retrospective Studies, Tablets therapeutic use, Anti-HIV Agents therapeutic use, Dideoxynucleosides therapeutic use, Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination therapeutic use, Emtricitabine, Rilpivirine, Tenofovir Drug Combination therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Lamivudine therapeutic use, Oxazines therapeutic use, Piperazines therapeutic use, Pyridones therapeutic use
- Abstract
Background: We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/DTG)] in a cohort of people living with HIV/AIDS (PLWH) under effective ART., Methods: All PLWH aged above 18 years on antiretroviral treatment with an HIV-RNA < 50 cp/mL at the time of the switch to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG were retrospectively included in the analysis. Framingham risk score modification after 12 months from the switch such as lipid profile and body weight modification were assessed. The change from baseline to 12 months in mean cardiovascular risk and body weight in each of the STR's group were assessed by means of Wilcoxon signed-rank test whereas a mixed regression model was used to assess variation in lipid levels., Results: Five-hundred and sixty PLWH were switched to an STR regimen of whom 170 (30.4%) to TAF/FTC/EVG/cobi, 191 (34.1%) to TAF/FTC/RPV and 199 (35.5%) to ABC/3TC/DTG. No difference in the Framingham cardiovascular risk score was observed after 12 months from the switch in each of the STR's groups. No significant overtime variation in mean total cholesterol levels from baseline to 12 months was observed for PLWH switched to ABC/3TC/DTG [200 (SD 38) mg/dl vs 201 (SD 35) mg/dl; p = 0.610] whereas a significant increment was observed in PLWH switched to TAF/FTC/EVG/cobi [192 (SD 34) mg/dl vs 208 (SD 40) mg/dl; p < 0.0001] and TAF/FTC/RPV [187 (SD 34) mg/dl vs 195 (SD 35) mg/dl; p = 0.027]. In addition, a significant variation in the mean body weight from baseline to 12 months was observed in PLWH switched to TAF/FTC/EVG/cobi [72.2 (SD 13.5) kilograms vs 74.6 (SD 14.3) kilograms; p < 0.0001] and TAF/FTC/RPV [73.4 (SD 11.6) kilograms vs 75.6 (SD 11.8) kilograms; p < 0.0001] whereas no difference was observed in those switched to ABC/3TC/DTG [71.5 (SD 12.8) kilograms vs 72.1 (SD 12.6) kilograms; p = 0.478]., Conclusion: No difference in the cardiovascular risk after 1 year from the switch to these STRs were observed. PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch.
- Published
- 2021
- Full Text
- View/download PDF
29. Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
- Author
-
Lombardi F, Giacomelli A, Armenia D, Lai A, Dusina A, Bezenchek A, Timelli L, Saladini F, Vichi F, Corsi P, Colao G, Bruzzone B, Gagliardini R, Callegaro A, Castagna A, and Santoro MM
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Coinfection, Drug Resistance, Multiple, Viral, Female, HIV Infections complications, HIV Infections transmission, HIV Integrase Inhibitors pharmacology, HIV Integrase Inhibitors therapeutic use, HIV Protease Inhibitors pharmacology, HIV Protease Inhibitors therapeutic use, Hepatitis B complications, Humans, Italy, Male, Retrospective Studies, Reverse Transcriptase Inhibitors pharmacology, Reverse Transcriptase Inhibitors therapeutic use, Risk Factors, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Infections virology, HIV-1 drug effects
- Abstract
Despite successful antiretroviral therapy (ART), patients infected with human immunodeficiency virus (HIV) can develop multi-class drug resistance (MDR). This retrospective study aimed to explore the prevalence of HIV-1 drug resistance over the past two decades by focusing on HIV-MDR and its predictors. ART-experienced patients with HIV with results from at least one plasma genotypic resistance test (GRT) from 1998 to 2018, from the Antiviral Response Cohort Analysis database, were included in this study. The temporal trend of resistance to any drug class was evaluated by considering all GRTs. Prevalence and predictors of HIV-MDR were analysed by consideration of cumulative GRTs. Among 15 628 isolates from 6802 patients, resistance to at least one drug class decreased sharply from 1998 to 2010 (1998-2001: 78%; 2008-2010: 59%; P<0.001) and then remained relatively constant at approximately 50% from 2011 to 2018, with the proportion of isolates with HIV-MDR also stable (approximately 9%). By evaluating factors associated with cumulative HIV-MDR, the following factors were found to be associated with increased risk of HIV-MDR on multi-variate analysis: male gender; sexual and vertical transmission; number of previous protease inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-NRTIs; previous exposure to integrase strand transfer inhibitors, enfuvirtide and maraviroc; and co-infection with hepatitis B virus. In contrast, a nadir CD4 cell count ≥200 cells/mm
3 , starting first-line ART in 2008 or later and co-infection with hepatitis C virus were associated with lower risk of HIV-MDR. In conclusion, this study revealed that HIV-1 drug resistance has been stable since 2011 despite its dramatic decrease over the past two decades. HIV-MDR is still present, although at a lower rate, suggesting the need for continuous surveillance and accurate management of ART-experienced patients with HIV., (Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
30. Ritonavir/Cobicistat-Induced Cushing Syndrome in HIV Patients Treated With Non-Oral Corticosteroids: A Call for Action?
- Author
-
Cattaneo D, Giacomelli A, Pagani G, Filice C, and Gervasoni C
- Subjects
- Adult, Anti-HIV Agents administration & dosage, Cushing Syndrome chemically induced, Cushing Syndrome prevention & control, Drug Interactions, Female, Humans, Italy, Male, Middle Aged, Retrospective Studies, Adrenal Cortex Hormones adverse effects, Anti-HIV Agents adverse effects, Cobicistat adverse effects, Cushing Syndrome diagnosis, HIV Infections drug therapy, Ritonavir adverse effects
- Published
- 2021
- Full Text
- View/download PDF
31. Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19.
- Author
-
Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, Atzori C, Ridolfo A, and Cattaneo D
- Subjects
- Adult, Antiviral Agents therapeutic use, Female, Hospitalization, Humans, Italy, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19 complications, HIV Infections complications
- Abstract
Little is known about the clinical outcomes of patients with human immunodeficiency virus infected with SARS-CoV-2. We describe 47 patients referred to our hospital between 21 February and 16 April 2020 with proven/probable COVID-19, 45 (96%) of whom fully recovered and 2 who died., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
32. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice.
- Author
-
Cattaneo D, Baldelli S, Resnati C, Giacomelli A, Meraviglia P, Minisci D, Astuti N, Ridolfo A, De Socio GV, Clementi E, Galli M, and Gervasoni C
- Subjects
- Antidepressive Agents blood, Antidepressive Agents therapeutic use, Antipsychotic Agents blood, Antipsychotic Agents therapeutic use, Female, HIV Seropositivity blood, Humans, Male, Mental Disorders drug therapy, Middle Aged, Psychotropic Drugs therapeutic use, HIV Infections blood, HIV Seronegativity, Psychotropic Drugs blood
- Abstract
Objectives: The management of psychiatric illness in HIV-infected patients is clinically challenging because of the risk of potential drug-drug interactions. Here, we aimed to measure the antidepressant and/or antipsychotic drug concentrations in HIV-infected patients during routine outpatient visits. Methods: Six hundred HIV-infected patients were screened during the first 15 months after the introduction of our outpatient polytherapy management service in a search for subjects treated with psychotropic drugs for at least 3 months. The distribution of psychotropic drug concentrations in HIV-infected patients was compared with that observed in a control group of HIV-negative patients monitored over the same period. Results: The search identified 82 HIV-infected patients concomitantly receiving antiretroviral and psychotropic drug treatment, 55% of whom had plasma psychotropic drug concentrations that were below minimum effective levels. The same result was found in only 26% of the samples taken from HIV-negative patients. These results were not affected by patients' gender, age, adherence to therapies or drug-drug interactions. Conclusions: A higher rate of sub-therapeutic antidepressant and/or antipsychotic drugs concentrations were found in HIV-infected patients. The creation of multidiscliplinary specialist teams may contribute to improving the management of such complex patients.
- Published
- 2020
- Full Text
- View/download PDF
33. The crosstalk between antiretrovirals pharmacology and HIV drug resistance.
- Author
-
Giacomelli A, Pezzati L, and Rusconi S
- Subjects
- Anti-HIV Agents pharmacokinetics, Anti-HIV Agents pharmacology, Drug Development, Drug Resistance, Viral, HIV Infections virology, HIV-1 drug effects, HIV-1 isolation & purification, Humans, Anti-HIV Agents administration & dosage, HIV Infections drug therapy
- Abstract
Introduction: The clinical development of antiretroviral drugs has been followed by a rapid and concomitant development of HIV drug resistance. The development and spread of HIV drug resistance is due on the one hand to the within-host intrinsic HIV evolutionary rate and on the other to the wide use of low genetic barrier antiretrovirals., Areas Covered: We searched PubMed and Embase on 31 January 2020, for studies reporting antiretroviral resistance and pharmacology. In this review, we assessed the molecular target and mechanism of drug resistance development of the different antiretroviral classes focusing on the currently approved antiretroviral drugs. Then, we assessed the main pharmacokinetic/pharmacodynamic of the antiretrovirals. Finally, we retraced the history of antiretroviral treatment and its interconnection with antiretroviral worldwide resistance development both in , and middle-income countries in the perspective of 90-90-90 World Health Organization target., Expert Opinion: Drug resistance development is an invariably evolutionary driven phenomenon, which challenge the 90-90-90 target. In high-income countries, the antiretroviral drug resistance seems to be stable since the last decade. On the contrary, multi-intervention strategies comprehensive of broad availability of high genetic barrier regimens should be implemented in resource-limited setting to curb the rise of drug resistance.
- Published
- 2020
- Full Text
- View/download PDF
34. Multidrug-resistant HIV viral rebound during early syphilis: a case report.
- Author
-
Giacomelli A, Micheli V, Cattaneo D, Mancon A, and Gervasoni C
- Subjects
- Coinfection, HIV Infections virology, Humans, Leukocytes, Mononuclear virology, Male, Middle Aged, Oxazines, Phylogeny, Piperazines, Pyridones, RNA, Viral blood, Sexual and Gender Minorities, Syphilis microbiology, Treponema pallidum, Viral Load drug effects, Anti-HIV Agents therapeutic use, Darunavir therapeutic use, Drug Resistance, Multiple, Viral genetics, HIV Infections complications, HIV Infections drug therapy, HIV-1 genetics, Heterocyclic Compounds, 3-Ring therapeutic use, Syphilis complications
- Abstract
Background: Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range., Case Presentation: This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA., Conclusions: This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus.
- Published
- 2020
- Full Text
- View/download PDF
35. Association of HIV Infection with Epilepsy and Other Comorbid Conditions.
- Author
-
Cattaneo D, Giacomelli A, Minisci D, Astuti N, Meraviglia P, and Gervasoni C
- Subjects
- Adolescent, Adult, Comorbidity, Epilepsy diagnosis, Epilepsy epidemiology, Female, HIV Infections drug therapy, HIV Infections psychology, Humans, Incidence, Male, Mental Disorders psychology, Middle Aged, Retrospective Studies, Anticonvulsants therapeutic use, Epilepsy drug therapy, HIV Infections epidemiology, Mental Disorders epidemiology
- Abstract
Here, we aimed to investigate the associations of comorbidities in HIV patients given antiepileptic drugs. HIV patients given antiepileptic drugs for at least 6 months were considered. Comorbidities of the epileptic, HIV-positive patients were stratified according to patients' age and causes of epilepsy. Seventy-four of the 97 HIV patients identified had at least one comorbidity. Patients more than 50-years old had more comorbidities (1.9 ± 1.5 vs. 1.1 ± 1.2, p < 0.01) compared with younger subjects. The distribution of the psychiatric disorders was comparable between age-related categories. A marginally significant trend for higher frequency of psychiatric disorders was observed in patients with idiopathic epilepsy versus other causes of epilepsy (43% vs. 24%), Because the presence of comorbid disorders is a major driver for premature mortality both in HIV infection and epilepsy, strategies aimed at favoring prevention, early identification, and adequate treatment in these clinical settings should be pursued at all levels of care.
- Published
- 2020
- Full Text
- View/download PDF
36. Overlooked cases of HIV infection: An Italian tale of missed diagnostic opportunities.
- Author
-
van den Bogaart L, Ranzani A, Oreni L, Giacomelli A, Corbellino M, Rusconi S, Galli M, Antinori S, and Ridolfo AL
- Subjects
- Aged, Delayed Diagnosis, Early Diagnosis, Humans, Italy epidemiology, Middle Aged, Retrospective Studies, HIV Infections diagnosis, HIV Infections epidemiology
- Abstract
Background: Late diagnoses are still a cause of increased HIV-related morbidity and mortality despite the availability of highly effective treatments. The aim of this study was to identify indicator conditions (ICs) in late presenters with HIV infection (LPs) that may represent missed opportunities of undertaking earlier HIV testing., Methods: The medical records of LPs referred to a specialist clinic in Milan, Italy, between 2011 and 2017 were reviewed to assess the frequency of ICs during the five years preceding diagnosis. Logistic regression analysis was used to investigate the factors associated with missed opportunities of making an earlier diagnosis., Results: The analysis considered 203 LPs (60.6% of the patients newly diagnosed as having HIV infection during the study period). Most had had ≥1 medical encounter in the five years before diagnosis, and 54 (26.6%) had been diagnosed as having ≥1 IC without undergoing HIV testing. The most frequent ICs were herpes zoster (19.8%), constitutional symptoms (17.4%) and lympho/thrombocytopenia (12.8%), and the missed opportunities for testing occurred in the settings of primary care (44.9%), specialist medical (38.2%) or surgical services (11.3%), and emergency departments (5.6%). Twenty-five (53.2%) of the 47 subjects with a non AIDS-defining IC had AIDS at the time of the diagnosis of HIV infection. Subjects aged >60 years were at increased risk of missed diagnostic opportunities (aOR 4.80, p = 0.008)., Conclusion: Implementing IC-guided HIV testing in non-specialist settings is an essential means of reducing late diagnoses of HIV infection even in the case of older subjects., Competing Interests: Declaration of Competing Interest SR declares participation to advisory boards, CME activities and research grants from BMS, MSD, Janssen, Gilead and ViiV/GSK. AG has received consultancy payments from Mylan. MG has received research grants, consultancy payments and speaker's fees from Bristol-Myers-Squibb, Gilead, ViiV/GSK, Merck Sharp Dohme, ABBvie, Janssen and Roche. The authors report no other conflicts of interest in this work., (Copyright © 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
- Author
-
Ciccullo A, Baldin G, Capetti A, Borghi V, Sterrantino G, Latini A, Madeddu G, Celani L, Vignale F, Rossetti B, Dusina A, Cossu MV, Restelli S, Gennari W, Lagi F, Giacomelli A, Colafigli M, Brescini L, Borghetti A, Mussini C, Rusconi S, and Di Giambenedetto S
- Subjects
- Adult, CD4 Lymphocyte Count, Cohort Studies, Drug Therapy, Combination, Female, Humans, Italy, Lamivudine therapeutic use, Male, Middle Aged, Oxazines, Piperazines, Pyridones, Rilpivirine therapeutic use, Treatment Outcome, Anti-Retroviral Agents therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use
- Abstract
Purpose: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) cohort was established in Italy in 2016 to evaluate the overall efficacy and tolerability of dolutegravir (DTG)-based antiretroviral (ARV) regimens in clinical practice., Participants: The ODOACRE cohort enrols all adult HIV-1-infected patients, both treatment-naïve and treatment-experienced, starting a DTG-based ARV regimen, in 11 clinical centres in Italy from 2014., Findings to Date: In recent years, various works by the ODOACRE cohort have been produced, demonstrating the high efficacy and tolerability of DTG-based ARV regimens in clinical practice, both in ART-naïve (in the setting of acute HIV-1 infection and late presenters patient) and experienced patients. We confirmed the virological efficacy of DTG-based regimens and we evaluated predictors of virological failure. We investigated cause of discontinuation and evaluated tolerability and metabolic profile of the regimens. Within these investigations, we explored particularly the use of DTG in simplification in two-drug regimen with either rilpivirine or lamivudine. We also compared DTG-based regimens with other integrase inhibitors in clinical practice., Future Plans: To continue to study long-term efficacy and tolerability of DTG-based regimens is the purpose of the ODOACRE cohort., Competing Interests: Competing interests: GB received travel grant from Gilead. ACa has received a personal grant from AB, Gilead and ViiV. GS has received funds for speaking by Gilead, Merk, Janssen, Abbvie, ViiV. AL received personal fees from BMS, Gilead, Merck, ViiV, AbbVie and Janssen and grants from BMS, Gilead, ViiV and Janssen. GM is in an ongoing relation as board member for ViiV Healthcare, Gilead Sciences and Jannsen. BR received travel grants from Jannsen, ViiV, Gilead MSD and received grants for consultancy from Abbvie, MSD, Viiv. AG received speaker fees from Mylan. AB has received non-financial support from Bristol-Myers Squibb and ViiV Healthcare, and personal fees from Gilead Sciences. CM has participated in advisory boards, received study grants and/or speaker honoraria from Abbvie, Gilead, Viiv, Janssen, Angelini, BMS and MSD. SR received research grants to his Institution from ViiV Heathcare, Gilead Sciences and Jannsen, outside the submitted work; he was also a paid consultant for ViiV Heathcare, Gilead Sciences, Merck Sharp and Dohme, Bristol-Myers Squibb, Janssen and Mylan. SDG was a paid consultant or member of advisory boards for Gilead, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme and Bristol-Myers Squibb., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
38. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
- Author
-
Giacomelli A, Lai A, Franzetti M, Maggiolo F, Di Giambenedetto S, Borghi V, Francisci D, Magnani G, Pecorari M, Monno L, Vicenti I, Lepore L, Lombardi F, Paolucci S, and Rusconi S
- Subjects
- Adult, Dideoxynucleosides therapeutic use, Drug Combinations, Female, Genes, Viral, HIV-1 genetics, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Lamivudine therapeutic use, Male, Middle Aged, Mutation, Oxazines, Piperazines, Pyridones, Retrospective Studies, Tenofovir therapeutic use, Viral Load, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, Drug Resistance, Viral drug effects, Drug Resistance, Viral genetics, HIV Infections drug therapy
- Abstract
The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) backbone could affect the virological efficacy of the regimen. Our aim was to assess the impact of previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of virological failure (VF) in patients, under virological control, who switched to dolutegravir (DTG)+2NRTIs regimens. All HIV-1 positive drug-experienced patients who started a regimen composed by DTG+2NRTIs [abacavir/lamivudine or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)/emtricitabine (FTC)] in the ARCA collaborative group with HIV-RNA <50 cp/mL were included in the analysis. Patients with a previous VF to integrase inhibitors were excluded. The impact of single and combined NRTIs mutations on the probability of VF (defined as 2 consecutive HIV-RNA >50 copies/mL or one HIV-RNA >1000 copies/mL) was assessed by Kaplan Meier curves. A multivariable Cox regression analysis was constructed to assess factors potentially related to VF. Five hundred and eighty-eight patients were included in the analysis with a median time of viral suppression before the switch of 37 months (IQR 12-78), of whom 148 (25.2%) had at least one previous NRTIs resistance mutation. In the multivariable model no association was observed between NRTIs mutations and VF. Conversely, the duration of viral suppression before switch resulted associated with a lower risk of VF (for 1 month increase, adjusted Hazard Ratio 0.98, 95%CI 0.96-0.99; p=0.024). Previous NRTIs mutations appeared to have no impact on the risk of VF in patients switched to DTG+2NRTIs, whereas a longer interval on a controlled viremia decreased significantly the risk of VF., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
39. Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
- Author
-
Baldin G, Ciccullo A, Rusconi S, Madeddu G, Sterrantino G, Freedman A, Giacometti A, Celani L, Latini A, Rossetti B, Cossu MV, Giacomelli A, Lagi F, Capetti A, and Di Giambenedetto S
- Subjects
- Adult, Cohort Studies, Drug Combinations, Female, Humans, Male, Middle Aged, Oxazines, Piperazines, Pyridones, Retrospective Studies, Tablets, Treatment Outcome, Anti-HIV Agents administration & dosage, Dideoxynucleosides administration & dosage, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring administration & dosage, Lamivudine administration & dosage
- Abstract
We investigated the effectiveness and safety of a dual therapy (DT) with lamivudine plus dolutegravir versus a single tablet regimen (STR) with abacavir/lamivudine/dolutegravir. We performed a retrospective analysis in a cohort of virologically suppressed HIV+ patients switching to lamivudine-dolutegravir or abacavir/lamivudine/dolutegravir. We evaluated the incidence of virological failure and treatment discontinuation, as well as their predictors. Non-parametric tests were applied to assess changes in immunological and metabolic parameters. In all, 616 patients were analyzed: 380 began STR and 236 DT. In the STR group three patients experienced VF; in the DT group seven patients experienced VF. No differences in cause of treatment discontinuation were found. The estimated probability of continuing therapy at 48 weeks were 88.5 % in DT and 90.3% in STR, without a statistically significant difference (Log-rank 0.338). Regarding the metabolic profile, in the STR group there was a reduction in LDL cholesterol levels at week 48 (p=0.008), whereas in the lamivudine group there was a significant reduction in total cholesterol level at week 48 (p=0.044). Regarding the renal function, in both groups we registered a reduction in estimated glomerular filtration rate (eGFR), with a median reduction of 8.4 ml/min in the STR group (p<0.001) and 10.2 mL/min in DT (p<0.001). We found a difference in strategy option: in a context of side effect and comorbidities, dual therapy strategy was preferred. Conversely, simplification and compliance improvement more frequently translated into a DTG-STR strategy.
- Published
- 2019
40. Impact of genotypic susceptibility score on cART outcomes during primary HIV infection.
- Author
-
Giacomelli A, Fabbiani M, De Benedetto I, Nozza S, Focà E, Celesia BM, Marchetti G, Mussini C, Antinori A, d'Ettorre G, Madeddu G, Bandera A, Muscatello A, and Rusconi S
- Subjects
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Retrospective Studies, Anti-HIV Agents administration & dosage, Anti-HIV Agents therapeutic use, HIV genetics, HIV Infections drug therapy
- Abstract
To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P = .005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P = .025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
41. Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis.
- Author
-
Cattaneo D, Baldelli S, Giacomelli A, Minisci D, Meraviglia P, Astuti N, Fusi M, Cozzi V, Clementi E, Galli M, and Gervasoni C
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Anticonvulsants blood, Anticonvulsants therapeutic use, Female, HIV Infections blood, HIV Infections drug therapy, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Anticonvulsants pharmacokinetics, HIV Infections metabolism
- Abstract
Introduction: A higher rate of subtherapeutic psychotropic drug concentrations was recently found in HIV-infected versus HIV-negative patients. In this study, we sought to investigate if this trend could also apply to antiepileptic drugs., Methods: Overall, 700 HIV-infected patients were screened during the first 2 years after the introduction of our outpatient polytherapy management service (Gestione Ambulatoriale Politerapie [GAP]) in the search for subjects with antiepileptic drug trough concentration assessments. The distribution of such concentrations was compared with that in HIV-negative patients monitored over the same period., Results: The search identified 97 HIV-infected patients concomitantly receiving antiretroviral and antiepileptic drugs, for a total of 310 drug measurements. Overall, 30%, 64% and 6%, versus 28%, 65% and 7%, of the antiepileptic concentrations measured in HIV-infected versus HIV-negative patients (1090 patients, for a total of 3488 antiepileptic concentrations measured) were below, within, or above the therapeutic targets, respectively. The antiepileptic drug valproate was associated with the highest risk of subtherapeutic drug concentrations, with 57% and 46% of determinations below the therapeutic range in HIV-positive and HIV-negative patients, respectively. Remarkably, the concentrations of valproate were significantly lower in HIV-infected versus HIV-negative patients (47.9 ± 21.2 versus 53.9 ± 21.6 mg/L; p < 0.05)., Conclusion: In our retrospective study, most HIV-infected patients had antiepileptic drug concentrations falling within the therapeutic targets, with the exception of valproate, which was associated with a higher rate of subtherapeutic concentrations compared with other antiepileptic drugs.
- Published
- 2019
- Full Text
- View/download PDF
42. Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.
- Author
-
Giacomelli A, Ranzani A, Oreni L, Gervasi E, Lupo A, Ridolfo AL, Galli M, and Rusconi S
- Subjects
- Cohort Studies, HIV Infections metabolism, Humans, Oxazines, Piperazines, Pyridones, Retrospective Studies, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Integrase Inhibitors therapeutic use, Heterocyclic Compounds, 3-Ring therapeutic use, Protease Inhibitors therapeutic use, Raltegravir Potassium therapeutic use
- Abstract
Purpose: Integrase inhibitor (INI)-containing regimens are increasingly replacing protease inhibitor(PI)-containing regimens in clinical practice. The aim of this study was to evaluate the determinants of the durability of INI-containing regimens after the switch., Patients and Methods: We retrospectively analysed all of the people with HIV infection attending the University of Milan's Infectious Diseases Unit at Luigi Sacco Hospital who were switched from a PI- to an INI-containing regimen between April 2008 and March 2017. The probability of remaining on an INI-containing regimen was estimated using Kaplan-Meier curves, and the baseline clinical predictors of INI-containing regimen durability were assessed using a multivariable Cox proportional hazard regression model., Results: Three hundred and twelve patients were included in the analysis. The median time of observation was 21 months (interquartile range 10-36 months). The main reasons for switching from a PI-containing regimen to an INI-containing regimen were toxicities (31.4%) and simplification (31.1%). Univariate analysis revealed no difference in the probability of INI discontinuation between the patients treated with raltegravir, dolutegravir or elvitegravir ( p =0.060), but the multivariable Cox regression model showed that the patients treated with dolutegravir were at less risk of discontinuation than those treated with raltegravir (adjusted hazard ratio 0.49, 95% confidence interval 0.26-0.95; p =0.034)., Conclusion: Switching from a PI- to an INI-containing regimen may be an option for patients under virological control. The patients switched to dolutegravir were less likely to discontinue the INI than those switched to raltegravir. Our findings support this therapeutic strategy and highlight the durability and efficacy of dolutegravir containing-regimens after switching from a PI-containing regimen., Competing Interests: SR has received research grants, consultancy payments and speaker’s fees from Bristol-Myers Squibb, Gilead, ViiV Healthcare, Merck Sharp Dohme, ABBvie and Janssen. MG has received research grants, consultancy payments and speaker’s fees from Bristol-Myers Squibb, Gilead, ViiV Healthcare, Merck Sharp Dohme, ABBvie, Janssen and Roche. The authors report no other conflicts of interest in this work.
- Published
- 2019
- Full Text
- View/download PDF
43. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
- Author
-
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, and Pozniak AL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases prevention & control, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Female, HIV Integrase Inhibitors adverse effects, HIV Protease Inhibitors adverse effects, Heterocyclic Compounds, 3-Ring adverse effects, Humans, Male, Middle Aged, Oxazines, Piperazines, Pyridones, Treatment Outcome, Young Adult, Antiretroviral Therapy, Highly Active methods, Drug Substitution methods, HIV Infections drug therapy, HIV Integrase Inhibitors administration & dosage, HIV Protease Inhibitors administration & dosage, Heterocyclic Compounds, 3-Ring administration & dosage, Lipids blood
- Abstract
Background: Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile., Methods: European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with a Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients were randomized to switch from PI/r to DTG immediately (DTG-I) or to deferred switch at week 48 (DTG-D). Week 96 endpoints were proportion of patients with HIV RNA <50 copies/mL, percentage change of lipid fractions, and adverse events (AEs)., Results: Four hundred fifteen patients were randomized: 205 to DTG-I and 210 DTG-D. The primary objective of noninferiority at week 48 was met. At week 96, treatment success rate was 92.2% in the DTG-I arm and 87% in the DTG-D arm (difference, 5.2% [95% confidence interval, -.6% to 11%]). There were 5 virological failures in the DTG-I arm and 5 (1 while on PI/r and 4 after switching to DTG) in the DTG-D arm without selection of resistance mutations. There was no significant difference in terms of grade 3 or 4 AEs or treatment-modifying AEs. Total cholesterol and other lipid fractions (except high-density lipoprotein) significantly (P < .001) improved both after immediate and deferred switching to DTG overall and regardless of baseline PI/r strata., Conclusions: Both immediate and deferred switching from a PI/r to a DTG regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved the lipid profile., Clinical Trials Registration: NCT02098837 and EudraCT: 2013-003704-39.
- Published
- 2019
- Full Text
- View/download PDF
44. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
- Author
-
Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, and Di Giambenedetto S
- Subjects
- Anti-HIV Agents administration & dosage, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cholesterol blood, Cohort Studies, Female, HIV-1, Humans, Male, Middle Aged, Oxazines, Piperazines, Pyridones, Viral Load, Drug Therapy, Combination, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring administration & dosage, Heterocyclic Compounds, 3-Ring therapeutic use, Lamivudine administration & dosage, Lamivudine therapeutic use, Rilpivirine administration & dosage, Rilpivirine therapeutic use
- Abstract
Background: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir (DTG)-based dual therapies: DTG plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group)., Methods: In a multicentre cohort of virologically suppressed (HIV RNA <50 copies/ml) HIV+ patients switching to DTG+3TC or DTG+RPV we analysed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors., Results: We analysed 416 patients, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 patients discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (1 developed non-nucleoside reverse transcriptase inhibitor mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak viral load >500,000 copies/ml in both treatment groups (log-rank P=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated with TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged., Conclusions: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.
- Published
- 2019
- Full Text
- View/download PDF
45. Clinical pharmacology in HIV cure research - what impact have we seen?
- Author
-
Giacomelli A, de Rose S, and Rusconi S
- Subjects
- Animals, Anti-HIV Agents pharmacology, Antibodies, Neutralizing immunology, Drug Discovery methods, Drug Therapy, Combination, HIV Infections immunology, HIV Infections virology, Humans, Molecular Targeted Therapy, Virus Latency physiology, Anti-HIV Agents administration & dosage, HIV Infections drug therapy, Virus Replication drug effects
- Abstract
Introduction : Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered : The present review assesses the principal pharmacological strategies that have been tested for an HIV cure starting from the in vitro proof of concept and the potential rationale of their in vivo applicability. We evaluated the possible pharmacological procedures employed during the early-stage HIV infection and the possibility of cART-free remission. We then analyzed the shock and kill approach from the single compounds in vitro mechanism of action, to the in vivo application of single or combined actions. Finally, we briefly considered the novel immunological branch through the discovery and development of broadly neutralizing antibodies in regard to the current and future in vivo therapeutic strategies aiming to verify the clinical applicability of these compounds. Expert opinion : Despite an incredible effort in HIV research cure, the likelihood of completely eradicating HIV is unreachable within our current knowledge. A better understanding of the mechanism of viral latency and the full characterization of HIV reservoir are crucial for the discovery of new therapeutic targets and novel pharmacological entities.
- Published
- 2019
- Full Text
- View/download PDF
46. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
- Author
-
Giacomelli A, Riva A, Falvella FS, Oreni ML, Cattaneo D, Cheli S, Renisi G, Di Cristo V, Lupo A, Clementi E, Rusconi S, Galli M, and Ridolfo AL
- Subjects
- Adult, Anti-HIV Agents administration & dosage, Anti-Retroviral Agents administration & dosage, Anti-Retroviral Agents adverse effects, Drug Therapy, Combination adverse effects, Female, Genetic Predisposition to Disease, HIV, HIV Infections complications, HIV Infections epidemiology, HIV Infections genetics, Humans, Male, Middle Aged, Nevirapine administration & dosage, Retrospective Studies, Risk Factors, Severity of Illness Index, Anti-HIV Agents adverse effects, Chemical and Drug Induced Liver Injury epidemiology, Chemical and Drug Induced Liver Injury genetics, HIV Infections drug therapy, Nevirapine adverse effects
- Abstract
Background: Nevirapine has been used as antiretroviral agent since early '90. Although nevirapine is not currently recommended in initial anti-HIV regimens, its use remains consistent in a certain number of HIV-1-positive subjects. Thus, our aim was to determine clinical and genetic factors involved in the development of severe nevirapine induced liver toxicity., Methods: We retrospectively analyzed all HIV positive patients who were followed at the Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan from May 2011 to December 2015. All patients treated with nevirapine who underwent a genotyping for the functional variants mapping into ABCB1, CYP2B6, CYP3A4 and CYP3A5 genes were included in the analysis. Severe hepatotoxicity was defined as ACTG grade 3-4 AST/ALT increase during the first three months of nevirapine treatment. The causality assessment between NVP exposure and drug-induced liver injury was performed by using the updated Roussel Uclaf Causality Assessment Methods. Hardy Weinberg equilibrium was tested by χ
2 test. A multivariable logistic regression model was constructed using a backward elimination method., Results: Three hundred and sixty-two patients were included in the analysis, of which 8 (2.2%) experienced a severe liver toxicity. We observed no differences between patients with and without liver toxicity as regards gender, ethnicity, age and immune-virological status. A higher prevalence of HCV coinfection (75.0% vs 30.2%; p = .0013) and higher baseline AST (58 IU/L vs 26 IU/L; p = 0.041) and ALT (82 IU/L vs 27 IU/L; p = 0.047) median levels were observed in patients with liver toxicity vs those without toxicity. The genotypes CT/TT at ABCB1 rs1045642 single nucleotide polymorphism (SNP), showed a protective effect for liver toxicity when compared with genotype CC (OR = 0.18, 95%CI 0.04-0.76; p = 0.020) in univariate analysis. In the multivariate model, HCV coinfection was independently associated with higher risk of developing liver toxicity (aOR = 8.00, 95%CI 1.27-50.29; p = 0.027), whereas ABCB1 rs1045642 CT/TT genotypes (aOR = 0.10, 95%CI 0.02-0.47; p = 0.004) was associated with a lower risk., Conclusions: According to our findings HCV coinfection and ABCB1 rs1045642 SNP represent independent determinants of severe liver toxicity related to nevirapine. This genetic evaluation could be included as toxicity assessment in HIV-1-positive subjects treated with nevirapine.- Published
- 2018
- Full Text
- View/download PDF
47. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?
- Author
-
Cattaneo D, Giacomelli A, and Gervasoni C
- Subjects
- Adult, Anti-Obesity Agents therapeutic use, Anti-Retroviral Agents therapeutic use, Cohort Studies, Comorbidity, Disease Progression, Drug Antagonism, Female, HIV drug effects, HIV physiology, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections pathology, Humans, Nonprescription Drugs therapeutic use, Polypharmacy, Preliminary Data, Treatment Failure, Viremia drug therapy, Anti-Obesity Agents adverse effects, Anti-Retroviral Agents antagonists & inhibitors, HIV Infections virology, Nonprescription Drugs adverse effects, Viremia pathology
- Abstract
Improved survival achieved by HIV-infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug-drug interactions. Here, evidence is provided that weight-loss drugs should be used with caution in HIV-infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over-the-counter medications, thus escaping the control of the physician., (© 2018 The Obesity Society.)
- Published
- 2018
- Full Text
- View/download PDF
48. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
- Author
-
Ranzani A, Oreni L, Agrò M, van den Bogaart L, Milazzo L, Giacomelli A, Cattaneo D, Gervasoni C, and Ridolfo AL
- Subjects
- Age Factors, Aged, Aged, 80 and over, Anti-HIV Agents therapeutic use, Anti-Retroviral Agents therapeutic use, Antipyretics adverse effects, Antipyretics therapeutic use, Calcium Channel Blockers adverse effects, Calcium Channel Blockers therapeutic use, Cross-Sectional Studies, Drug Interactions, Drug Therapy, Combination, Female, Humans, Italy, Logistic Models, Male, Middle Aged, Reverse Transcriptase Inhibitors adverse effects, Reverse Transcriptase Inhibitors therapeutic use, Risk Factors, Sex Factors, Anti-HIV Agents adverse effects, Anti-Retroviral Agents adverse effects, Comorbidity, Drug-Related Side Effects and Adverse Reactions, HIV Infections complications, HIV Infections drug therapy
- Abstract
Background: As HIV-infected patients aged 50 years or older are at increased risk of comorbidities and multidrug treatments, we examined their exposure to the potential drug-drug interactions (PDDIs) of antiretroviral (ARV) and other medications., Methods: This cross-sectional study involved the patients aged 50 years or older receiving ARV and non-ARV medications at our clinic. PDDIs were identified using the University of Liverpool HIV Drug Interaction Checker. Logistic regression models were used to assess risk factors for PDDIs. The American Geriatrics Society Beers Criteria were used to identify potentially inappropriate medications (PIMs)., Results: A total of 395 (53.9%) of 744 patients showed ≥1 PDDI: 47.4% ≥ 1 amber-PDDI (comedications requiring appropriate management) and 5.6% ≥ 1 red-PDDI (contraindicated comedications). A higher risk of PDDIs was associated with the use of ≥5 medications (P < 0.001), of antiosteoporotics (P < 0.001), calcium channel blockers (P < 0.001), anti-benign prostatic hypertrophy agents (P < 0.001), hypnotics/sedatives (P = 0.022), and anticoagulants (P = 0.006). A higher risk of red-PDDIs was associated with the use of antacids (P < 0.001), anti-benign prostatic hypertrophy agents (P < 0.001) and antipsychotics (P = 0.023). The use of nucleoside reverse transcriptase inhibitor + nonnucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor rather than protease inhibitor-based regimens was associated with a reduced risk of PDDIs (P < 0.001). Overall, 119 (16.0%) patients were receiving PIMs (mainly hypnotics/sedatives) and 49 (41.2%) of them had PDDIs able to increase the blood levels of these medications., Conclusions: Older patients with HIV are highly exposed to PDDIs between ARVs and comedications. The knowledge of their complete medication regimens and the screening for PDDIs and PIMs is therefore crucial to prevent drug-related adverse outcomes in this population.
- Published
- 2018
- Full Text
- View/download PDF
49. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
- Author
-
Cattaneo D, Minisci D, Baldelli S, Mazzali C, Giacomelli A, Milazzo L, Meraviglia P, Resnati C, Rizzardini G, Clementi E, Galli M, and Gervasoni C
- Subjects
- Adenine administration & dosage, Adenine pharmacokinetics, Adult, Aged, Alanine, Anti-HIV Agents administration & dosage, Cobicistat administration & dosage, Drug Combinations, Drug Interactions, Female, Heterocyclic Compounds, 3-Ring administration & dosage, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Oxazines, Piperazines, Proportional Hazards Models, Pyridones, Quinolones administration & dosage, Raltegravir Potassium administration & dosage, Ritonavir administration & dosage, Tenofovir administration & dosage, Tenofovir blood, Treatment Outcome, Adenine analogs & derivatives, Anti-HIV Agents pharmacology, Cobicistat pharmacokinetics, HIV Infections drug therapy, Tenofovir pharmacokinetics
- Abstract
Background: The dose of tenofovir alafenamide is reduced from 25 to 10 mg daily when given with boosting agents. However, such dose reduction has never been adopted for tenofovir disoproxil fumarate (TDF). In this study, we aim to quantify the effect of cobicistat (COBI) both on tenofovir concentrations and TDF durability in real life setting., Methods: HIV-positive patients receiving TDF-containing antiretroviral therapies with at least 1 assessment of tenofovir plasma trough concentrations were included in the study. Univariate and multivariate regression analyses were performed considering tenofovir concentration as the dependent variable and clinical characteristics as independent covariates. Subsequently, survival and Cox analyses were performed considering as the primary outcome TDF discontinuation for any reasons., Results: Patients were given TDF with protease inhibitors/ritonavir (n = 212), non-nucleoside reverse transcriptase inhibitors (n = 176), integrase inhibitors (dolutegravir or raltegravir, n = 46), or with elvitegravir/COBI (ELV/COBI) (n = 76). By multivariate analysis, concomitant antiretroviral therapies resulted significantly associated with tenofovir levels, with the highest drug concentrations measured in patients given ELV/COBI. By survival analysis, we found that patients given TDF with ELV/COBI had the lowest rate of drug durability. Overall, these patients had a 2.3-fold increased risk to experience TDF discontinuation., Conclusions: Coadministration with COBI resulted in significantly higher tenofovir concentrations and higher TDF discontinuation compared with other antiretroviral regimens. Accordingly, the possibility that the lack of proper dose adjustment for TDF when given with COBI might have biased the safety comparisons with tenofovir alafenamide during registrative trials cannot be ruled out.
- Published
- 2018
- Full Text
- View/download PDF
50. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
- Author
-
Sollima S, Antinori S, Torre A, Binda F, Giacomelli A, and Milazzo L
- Subjects
- Antiviral Agents pharmacology, Benzimidazoles administration & dosage, Benzimidazoles adverse effects, Coinfection, Fluorenes administration & dosage, Fluorenes adverse effects, HIV Infections complications, Hepatitis C, Chronic complications, Homosexuality, Male, Humans, Male, Middle Aged, Sofosbuvir administration & dosage, Sofosbuvir adverse effects, Treatment Outcome, Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Fluorenes therapeutic use, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy, Sofosbuvir therapeutic use
- Abstract
Here we describe the case of a HIV-positive patient with acute hepatitis C virus reinfection, who was successfully treated with an interferon-free regimen of ledipasvir/sofosbuvir.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.